Podcasts about Medical director

MedTech graveyards are full of clever devices that never made it past the demo. Dr. Tori O'Daniel (OB/GYN, Medical Director, Oklahoma City) walks us through the five adoption pillars that separate shelf-ware from standard-of-care.In This Episode• The “ease-of-use” litmus test every new device must pass• Why education is a FOREVER activity, not a launch event• How to spot (and empower) your Champion-for-Change• Talking cost: shifting the conversation from unit price to total value• Template-driven VAC submissions that save months of back-and-forth

This episode recorded live at the Becker's 22nd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference features Dr. Scott Hannum, Partner at Emerge Ortho and President and Medical Director of Brunswick Surgery Center. Dr. Hannum shares insights on the shift of orthopedic procedures to outpatient settings, challenges with ASC regulations and reimbursement, and the role of technology and independent partnerships in driving future growth.

Join us for this month's episode of Hancock Talks as host Carly Brooks talks with Dr. Magdalena Kluchko, a board-certified Internist and Medical Director at John Hancock. Gain valuable insights that can elevate your practice, from the essential role medical directors play in the insurance industry to medical developments that could impact your clients. Tune in to explore:Enhancing underwriting decision-making: Discover how Dr. Kluchko's expertise helps our team deliver the best-possible decisions — and learn how you can contribute to this process.  Emerging medical trends: Explore the potential impact of top-of-mind advancements like GLP-1 medications.Practical applications for producers: Get tips on incorporating new medical insights to improve client conversations. INTENDED FOR FINANCIAL PROFESSIONAL USE ONLY. NOT INTENDED FOR USE WITH THE GENERAL PUBLIC.Insurance products are issued by: John Hancock Life Insurance Company (U.S.A.), Boston, MA 02116 (not licensed in New York) and John Hancock Life Insurance Company of New York, Valhalla, NY 10595.MLINY062725160-4

Daughters of three civil rights leaders share how their parents shaped their lives while also fighting for racial equality.Then, a new gas tax goes into effect next week. An official with MDOT shares what that means for drivers.Plus, we talk with the new Medical Director for the Mississippi Department of Health. Hosted on Acast. See acast.com/privacy for more information.

Dr Dean George is the Medical Director of Cutaneous Oncology at Hartford Healthcare Cancer Institute. He says with the Sun beaming down now, it is important to know the facts about skin cancer and how to protect yourself from it.

Any mid-life woman knows that once you hit your 40s, 50s, or 60s, things will not go well if you eat the same way you did when you were 20. But it's confusing to know what to eat, and how much to eat, without downloading multiple APPs and carrying around a calculator  My guest, Alexandra Filingeri, holds a doctorate in Clinical Nutrition with a focus on evidence-based nutrition interventions, particularly in mid-life and menopause.  In this episode, we cover practical nutrition tips- what to eat and how much to eat to maximize health aging. Dr. Filingeri also answered questions that came in from my Substack readers.  By the way, my favorite frozen vegetables that I couldn't remember the name of?  Puravida Fire Roasted Vegetable Melange What changes post menopause Obesity, hot flashes and weight loss The impact of insomnia on weight Individual energy requirements Macronutrients vs micronutrients Protein supplements- yay or nay Glycemic index Sugar and belly fat Grocery store strategies Dr. Alexandra Filingeri is a Registered Dietitian with a Doctorate degree in Clinical Nutrition. During her doctoral studies, Dr. Filingeri focused on metabolic disorders, nutritional biochemistry, and clinical research methodologies, equipping herself to deliver evidence-based nutrition interventions. Her clinical expertise focuses on midlife nutrition and hormone-related health.  Website: Nutrition by Dr. Alexandra – Beauty From The Inside Out Instagram: Dr. Alexandra Filingeri DCN RDN (@nutritionby_dralexandra) • Instagram photos and videos  Linkedln: Alexandra Filingeri, DCN RDN - Registered Dietitian in Private Practice - Nutrition By Dr Alexandra | LinkedIn Dr. Streicher is on SUBSTACK      DrStreicher.Substack.com Articles Monthly newsletter All COME AGAIN podcast episodes Monthly News Flash Reports on recent research  Monthly Zoom Ask Me Anything Webinar    Information on Dr. Streicher's COME AGAIN Podcast- Sexuality and Orgasm   Lauren Streicher MD, is a clinical professor of obstetrics and gynecology at Northwestern University's Feinberg School of Medicine, the founding medical director of the Northwestern Medicine Center for Sexual Medicine and Menopause, and a Senior Research Fellow of The Kinsey Institute, Indiana University. She is a certified menopause practitioner of The Menopause Society. She is the Medical Director of Community Education and Outreach for Midi Health.   Dr. Streicher is the medical correspondent for Chicago's top-rated news program, the WGN Morning News, and has been seen on The Today Show, Good Morning America, The Oprah Winfrey Show, CNN, NPR, Dr. Radio, Nightline, Fox and Friends, The Steve Harvey Show, CBS This Morning, ABC News Now, NBCNightlyNews,20/20, and World News Tonight. She is an expert source for many magazines and serves on the medical advisory board of The Kinsey Institute, Self Magazine, and Prevention Magazine. She writes a regular column for The Ethel by AARP and Prevention Magazine.    LINKS Subscribe To Dr. Streicher's Substack Information About the COME AGAIN Podcast Dr. Streicher's CV and additional bio information To Find a Menopause Clinician and Other Resources  Glossary Of Medical Terminology Books by Lauren Streicher, MD  Slip Sliding Away: Turning Back the Clock on Your Vagina-A gynecologist's guide to eliminating post-menopause dryness and pain Hot Flash Hell: A Gynecologist's Guide to Turning Down the Heat Sex Rx- Hormones, Health, and Your Best Sex Ever The Essential Guide to Hysterectomy                                      Dr. Streicher's Inside Information podcast is for education and information and is not intended to replace medical advice from your personal healthcare clinician. Dr. Streicher disclaims liability for any medical outcomes that may occur because of applying methods suggested or discussed in this podcast.             

Looking to take your career above and beyond? You'll want to hear this. This week, we're joined by Dr. Stephen Lewellis as he walks us through what it means to go above and beyond. Listen in as he describes the pros and cons of owning your own practice, when to make changes in your career, and how to tell your own story to patients and peers alike. Each Thursday, join Dr. Raja and Dr. Hadar, board-certified dermatologists, as they share the latest evidence-based research in integrative dermatology. For access to CE/CME courses, become a member at LearnSkin.com.   Stephen Lewellis, MD, PhD, FAAD is a board-certified dermatologist with expertise in both conventional and integrative dermatology. He earned his MD and PhD from the NYU Grossman School of Medicine and completed his dermatology residency at Stanford University. He is the founder of Above & Beyond Dermatology, an independent integrative dermatology practice in central Wisconsin offering office visits, virtual care, and house calls. He also serves as the Medical Director of Skinnovations Medical Aesthetics and hosts Above & Beyond Dermatology, a podcast dedicated to challenging conventional wisdom in both patient care and business. Additionally, he is a Founding Medical Partner at Doctorpedia and the Executive Director of Dermatology at FirstHx. Dr. Lewellis is passionate about combining evidence-based care with functional medicine principles to treat skin, hair, and nail conditions—often achieving results that go beyond the surface. He serves his team, patients, and audience by upholding his Core Four Values: Hospitality, Trust, Access, and Accountability.

Measles outbreak on BC Ferries Guest: Dr. Brian Conway, President and Medical Director at Vancouver Infectious Diseases Centre Learn more about your ad choices. Visit megaphone.fm/adchoices

Are you scared to travel right now? Guest: Jennifer Weatherhead, travel and style Can a new Canadian Social media site compete? Guest: Ben Waldman, CEO and Founder of Gander  How much time outside do we really need to be healthy? Guest: John Zelensky, Professor of Psychology at Carleton University Does Trump still want Canada to be the 51st State? Guest: Allison Gifford, Vice President, Policy and Public Affairs, Clear Strategies Richmond controversies continue to multiply Guest: Kash Heed, Richmond City Councillor Measles outbreak on BC Ferries Guest: Dr. Brian Conway, President and Medical Director at Vancouver Infectious Diseases Centre Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr Steven Lazar is a pediatric neurologist specializing in detection, diagnosis, and management of neurodevelopmental disorders. He is also the Medical Director of Neonatal Developmental Follow-Up Clinics for Texas Children's Hospital, and is here today to teach us about modern understanding and study of ADHD and Autism, and his focus on individualized and strength-based treatment.  With so much misunderstanding and disinformation about ASD & ADHD, Dr Lazar is one of many medical researchers helping to share science-based information. Follow him and his work @smlazarMD on Instagram and BluSky.  Visit www.covenanthousecalifornia.org to support this month's highlighted charity, helping homeless youth in California to find safety and stability. 

In this episode of The Healers Café, Manon Bolliger, FCAH, RBHT (facilitator and retired naturopath with 30+ years of practice) speaks to Dr. Eva Selhub: A Journey of Healing and Transformation - From Harvard Medical School to Holistic Resiliency, Exploring the Power of Mind-Body Medicine, Personal Growth, and Empowering Patients Through Curiosity, Compassion, and Innovative Approaches to Health and Well-being.   For the transcript and full story go to: https://www.drmanonbolliger.com/dr-eva-selhub        Highlights from today's episode include:   A transformative conversation with Dr. Eva Selhub, exploring her journey from traditional medicine to holistic healing, revealing how resilience, curiosity, and empowerment can reshape our approach to health and personal growth.   Dr. Selhub's emphasis on empowering patients and clients rather than keeping them in a victim mindset   Manon Bolliger we can definitely explore questions so that that they're thinking what other choices might be available to them, and it may position the work with fascia and with Bowen in a very positive light   ABOUT DR. EVA SELHUB: Dr. Eva Selhub is an internationally recognized resiliency expert  thought leader, physician, author, executive coach, keynote speaker, and spiritual advisor. With almost three decades of experience, she previously held roles as an Instructor of Medicine at Harvard Medical School and as a Clinical Associate at the prestigious Benson Henry Institute for Mind-Body Medicine at Massachusetts General Hospital, where she also served as Medical Director for six years. Dr. Selhub also served as an adjunct scientist of neuroscience at Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, one of six human nutrition research centers supported by the United States Department of Agriculture (USDA).   Dr. Selhub now collaborates with clients and organizations, leveraging her expertise to redefine leadership and wellbeing paradigms. Dr. Selhub possesses a unique talent for distilling complex scientific and spiritual concepts into practical, accessible knowledge. Her transformative energy, intuitive guidance, scientific expertise, and practical mindset inspire profound change and growth in her clients and audiences worldwide.  She is the author of six books, including: Burnout for Dummies, Resilience for Dummies, Your Health Destiny, The Stress Management Handbook, The Love Response.  Additionally, she co-authored:  Your Brain on Nature and has been featured in esteemed publications like The New York Times, authored multiple scientific publications, and has been showcased on national and international media platforms. Core purpose/passion: I want to bring hope to humanity of the infinite possibilities that are available to us to  heal and live a full and rich life. That magic can be normal. Website | Facebook | LinkedIn | Instagram | YouTube | TikTok | Twitter   ABOUT MANON BOLLIGER, FCAH, RBHT  As a de-registered (2021) board-certified naturopathic physician & in practice since 1992, I've seen an average of 150 patients per week and have helped people ranging from rural farmers in Nova Scotia to stressed out CEOs in Toronto to tri-athletes here in Vancouver.  My resolve to educate, empower and engage people to take charge of their own health is evident in my best-selling books:  'What Patients Don't Say if Doctors Don't Ask: The Mindful Patient-Doctor Relationship' and 'A Healer in Every Household: Simple Solutions for Stress'.  I also teach BowenFirst™ Therapy through and hold transformational workshops to achieve these goals.  So, when I share with you that LISTENING to Your body is a game changer in the healing process, I am speaking from expertise and direct experience"  Manon's Mission: A Healer in Every Household!  For more great information to go to her weekly blog:  http://bowencollege.com/blog.  For tips on health & healing go to: https://www.drmanonbolliger.com/tips    Follow Manon on Social – Facebook | Instagram | LinkedIn | YouTube | Twitter | Linktr.ee | Rumble   ABOUT THE HEALERS CAFÉ:  Manon's show is the #1 show for medical practitioners and holistic healers to have heart to heart conversations about their day to day lives.  Subscribe and review on your favourite platform: iTunes | Google Play | Spotify | Libsyn | iHeartRadio | Gaana | The Healers Cafe | Radio.com | Medioq |   Follow The Healers Café on FB: https://www.facebook.com/thehealerscafe   Remember to subscribe if you like our videos. Click the bell if you want to be one of the first people notified of a new release.   * De-Registered, revoked & retired naturopathic physician after 30 years of practice in healthcare. Now resourceful & resolved to share with you all the tools to take care of your health & vitality!  

Beyond symptom management, can personalized hormone therapy unlock true longevity and address the subtle, often dismissed symptoms that impact women's health? This episode cuts through the noise to explore the evolving landscape of women's hormonal health, from early interventions to the nuances of bioidentical and body-identical hormones.Today, Dr. Emmie Brown, ND, and Melissa Gentile, INHC, welcome Dr. Nirusha Kumaran, Medical Director at the London-based Human Clinic, to discuss personalized hormone therapy, perimenopause, and the evolving landscape of women's health. Dr. Kumaran, a GP, lifestyle medicine physician, and functional medicine doctor, shares her personal journey into functional medicine, inspired by her daughter's health challenges and her own experience with debilitating period pain, which led her to discover the profound impact of dietary changes on her hormonal health.The conversation explores the distinction between "body-identical" (pharmaceutical-manufactured bioidenticals) and "bioidentical" (compounded) hormone replacement therapy, emphasizing the benefits of personalized dosages and preparations. Dr. Kumaran emphasizes the importance of starting HRT early, even in perimenopause, for long-term benefits in cardiovascular health, bone density, and overall longevity, moving beyond mere symptom control.Key Takeaways from Today's Episode:

This episode recorded live at the Becker's 22nd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference features Dr. Scott Hannum, Partner at Emerge Ortho and President and Medical Director of Brunswick Surgery Center. Dr. Hannum shares insights on the shift of orthopedic procedures to outpatient settings, challenges with ASC regulations and reimbursement, and the role of technology and independent partnerships in driving future growth.

This episode recorded live at the Becker's 22nd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference features Dr. Scott Hannum, Partner at Emerge Ortho and President and Medical Director of Brunswick Surgery Center. Dr. Hannum shares insights on the shift of orthopedic procedures to outpatient settings, challenges with ASC regulations and reimbursement, and the role of technology and independent partnerships in driving future growth.

Professor John Kennedy, Medical Director of Trinity St James' Cancer Institute discusses the significance of being designated the country's first comprehensive cancer centre.

Dr. Mike Guertin, Professor of Anesthesiology and Chief Perioperative Medical Director at Ohio State University Wexner Medical Center, joins the podcast to reflect on the evolution of his career and the leadership lessons he's gained along the way. He discusses his experience in an MBA program and how it has shaped his approach to healthcare leadership. Dr. Guertin also sheds light on the ongoing anesthesia shortage and its implications for care delivery.

Assessment processes will still be rigorous for prescribing ADHD medication. From February, GPs and nurse practitioners will be able to prescribe treatments from the outset without a specialist recommendation. Wait times for specialist appointments vary but can be over a year. Royal College of GPs medical director Dr. Luke Bradford told Mike Hosking it's a good move to help people access diagnoses more quickly and affordably. He says it will be under a specialist interest type GP who will have to up-skill through training courses to prescribe. LISTEN ABOVE See omnystudio.com/listener for privacy information.

Rates of chronic illness, behavioral disorders, and neurodevelopmental challenges are rising rapidly among children, often tied to underlying gut dysfunction, nutrient deficiencies, and environmental triggers such as toxins and ultra-processed foods. Conventional treatments frequently overlook these root causes, relying instead on symptom management or medication. Functional approaches emphasize foundational lifestyle changes—clean nutrition, microbiome support, movement, sleep, and stress reduction—as powerful tools to restore health. Children are especially responsive to these changes, often experiencing rapid and dramatic improvements in behavior, mood, and physical symptoms. With education, testing, and family-centered strategies, parents can take simple, effective steps to help their children thrive. In this episode, I discuss, along with Dr. Elisa Song, Dr. Suzanne Goh, and Dr. Elizabeth Boham why a root-cause approach is just as important for children, as it is for adults. Dr. Elisa Song, MD is a Stanford-, NYU-, UCSF-trained integrative pediatrician, pediatric functional medicine expert, and mom to 2 thriving children - and she is on a mission to revolutionize the future of children's health. Dr. Song is the bestselling author of the Healthy Kids Happy Kids: An Integrative Pediatrician's Guide to Whole Child Resilience. Dr. Song created Healthy Kids Happy Kids as an online holistic pediatric resource to help practitioners and parents bridge the gap between conventional and integrative pediatrics with an evidence-based, pediatrician-backed, mom-approved approach. In her integrative pediatric practice, she's helped 1000s of kids get to the root causes of their health concerns and empowered parents to help their children thrive by integrating conventional pediatrics with functional medicine, homeopathy, acupuncture, herbal medicine, and essential oils. Dr. Song is chair of A4M's pediatric education and has lectured around the world at leading integrative and functional medicine conferences and premier parenting events. She has also been featured in hundreds of top podcasts, print and online media outlets, including the Wellness Mama podcast, BloomTV, Forbes, Healthline, MindBodyGreen, National Geographic, PopSugar, Parents, Motherly, Parade, Verywell Health, and New York Post. Dr. Suzanne Goh, co-founder and chief medical officer at Cortica, is a Rhodes Scholar and graduate of Harvard University, University of Oxford, and Harvard Medical School who has spent decades working with autistic children. Her work as a board-certified pediatric behavioral neurologist, behavioral analyst, neuroscience researcher, and author led her to create the Cortica Care Model, an innovative, whole-child approach that combines optimal medical treatment with the most effective strategies for advancing cognition, communication, and behavior. Dr. Elizabeth Boham is Board Certified in Family Medicine from Albany Medical School, and she is an Institute for Functional Medicine Certified Practitioner and the Medical Director of The UltraWellness Center. Dr. Boham lectures on a variety of topics, including Women's Health and Breast Cancer Prevention, insulin resistance, heart health, weight control and allergies. She is on the faculty for the Institute for Functional Medicine. This episode is brought to you by BIOptimizers. Head to bioptimizers.com/hyman and use code HYMAN10 to save 10%. Full-length episodes can be found here: How to Raise Healthy Kids: A Functional Medicine Approach The Surprising Causes of Autism & Why It's On The Rise Addressing The Root Causes Of Childhood Obesity

Ever feel like your body's changing and no one gave you the memo? In this candid and empowering episode, we unpack the often-overlooked realities of perimenopause—what's really happening with your hormones and why it can feel like everything from your mood to your memory is shifting. We dive into how this phase of life impacts sleep, mood, memory, libido, and long-term health. Dr. Jones also breaks down the latest thinking on hormone replacement therapy, clears up common misconceptions, and shares how supportive tools like seed cycling can offer natural relief.If you're navigating perimenopause or want to prepare for it with clarity and confidence, this episode is a must-listen.In this episode you'll learn: * What your hormones are really doing in every decade* The truth about HRT from a doctor's perspective* How perimenopause affects mood, sleep, memory, and libido* The top chronic diseases women face and their hormonal ties* How seed cycling can support you through perimenopause* And more…Carrie Jones, ND, FABNE, MPH, MSCP is an internationally recognized speaker, consultant, author and educator on the topic of women's health and hormones with over 20 years in the industry. Dubbed the “Queen of Hormones,” Dr. Jones is a Naturopathic Physician who did her 2-year residency focused on women's health and endocrinology. She went on to get her Master of Public Health (MPH), was one of the first to become board certified through the American Board of Naturopathic Endocrinology (FABNE), and is a Menopause Society Certified Practitioner (MSCP). She was the first Medical Director for Precision Analytical (the DUTCH Test), the first Head of Medical Education at Rupa Health and was on Under Armour's Human Performance Council. She co-hosted the highly popular show, the Root Cause Medicine Podcast that has over 10 million downloads and now hosts her own, Hello Hormones podcast. This episode is brought to you by beeya: * Learn more about beeya's seed cycling bundle at https://beeyawellness.com/free to find out how to tackle hormonal imbalances. * Get $10 off your order by using promo code BEHINDHEREMPIRE10Follow Yasmin: * Instagram: https://www.instagram.com/yasminknouri/* Stay updated & subscribe to our newsletter: https://www.behindherempire.com/Follow Dr. Carrie: * Instagram: https://www.instagram.com/dr.carriejones/* Website: https://www.drcarriejones.com/ Hosted on Acast. See acast.com/privacy for more information.

Southern Remedy Healthy and Fit is hosted by Josie Bidwell, Professor of Preventive Medicine and Nurse Practitioner at UMMC. If you have a question for Josie, you can email fit@mpbonline.org. It this episode, Josie talks about pain management with Dr. Kevin Vance, Medical Director of the Comprehensive Pain Management Center of Mississippi. Hosted on Acast. See acast.com/privacy for more information.

Dr. Jeff Bohmer, Medical Director of the Emergency Department at Northwestern Medicine Central DuPage Hospital, joins Jon Hansen (in for Bob Sirott) to talk about staying safe in extreme heat and if these prescription medications have a correlation for increased risk of dementia. He also explains the difference between sunscreen made in America versus Europe […]

This episode features Dr. Frederick L. Greene, Emeritus Chair of Surgery at Carolinas Medical Center and Medical Director of Cancer Data Services at Atrium Health-Levine Cancer Institute. Dr. Greene shares insights on improving cancer registries, the evolution of surgical oncology, and the future impact of robotics and AI on healthcare.

We all hope to grow old with dignity and some joyfulness. The intimate narratives of 40 extraordinary elders shared in I'll Fly Away: Stories About Amazing Disabled Elders explore both the challenges of aging and the joys and vibrancy that often persist in the twilight years. Poignant observations of the patients and families by a team of health professionals intersecting daily at the Center for Elders' Independence in Oakland, California, reveal the complexities of aging, identity, amid the assertive persistence of the human spirit. From a couple's summer drive across the Arizona desert to a family's struggle with mental illness to patients' romantic escapades, each tale offers a unique glimpse into the resilience of individuals facing profound transitions and prompts questions about our collective responsibility to our elders. Though this book is valuable for medical and public health professionals, it especially offers families kinship, support, and inspiration. For patients and readers in general, I'll Fly Away champions the idea that every one of us is a unique person with needs, wants, and a voice that is discoverable and deserves to be heard. It embodies the notion that every life is a story, and every voice matters. Marc Sapir, a retired primary care, geriatric and public health physician, is an essayist and political activist. He was first Medical Director of the Center for Elders' Independence for disabled elders for 9 years. He is author of five plays, and also writes fiction, poetry, and music. He lives in Berkeley, CA. Caleb Zakarin is editor of the New Books Network. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

We all hope to grow old with dignity and some joyfulness. The intimate narratives of 40 extraordinary elders shared in I'll Fly Away: Stories About Amazing Disabled Elders explore both the challenges of aging and the joys and vibrancy that often persist in the twilight years. Poignant observations of the patients and families by a team of health professionals intersecting daily at the Center for Elders' Independence in Oakland, California, reveal the complexities of aging, identity, amid the assertive persistence of the human spirit. From a couple's summer drive across the Arizona desert to a family's struggle with mental illness to patients' romantic escapades, each tale offers a unique glimpse into the resilience of individuals facing profound transitions and prompts questions about our collective responsibility to our elders. Though this book is valuable for medical and public health professionals, it especially offers families kinship, support, and inspiration. For patients and readers in general, I'll Fly Away champions the idea that every one of us is a unique person with needs, wants, and a voice that is discoverable and deserves to be heard. It embodies the notion that every life is a story, and every voice matters. Marc Sapir, a retired primary care, geriatric and public health physician, is an essayist and political activist. He was first Medical Director of the Center for Elders' Independence for disabled elders for 9 years. He is author of five plays, and also writes fiction, poetry, and music. He lives in Berkeley, CA. Caleb Zakarin is editor of the New Books Network. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/medicine

We all hope to grow old with dignity and some joyfulness. The intimate narratives of 40 extraordinary elders shared in I'll Fly Away: Stories About Amazing Disabled Elders explore both the challenges of aging and the joys and vibrancy that often persist in the twilight years. Poignant observations of the patients and families by a team of health professionals intersecting daily at the Center for Elders' Independence in Oakland, California, reveal the complexities of aging, identity, amid the assertive persistence of the human spirit. From a couple's summer drive across the Arizona desert to a family's struggle with mental illness to patients' romantic escapades, each tale offers a unique glimpse into the resilience of individuals facing profound transitions and prompts questions about our collective responsibility to our elders. Though this book is valuable for medical and public health professionals, it especially offers families kinship, support, and inspiration. For patients and readers in general, I'll Fly Away champions the idea that every one of us is a unique person with needs, wants, and a voice that is discoverable and deserves to be heard. It embodies the notion that every life is a story, and every voice matters. Marc Sapir, a retired primary care, geriatric and public health physician, is an essayist and political activist. He was first Medical Director of the Center for Elders' Independence for disabled elders for 9 years. He is author of five plays, and also writes fiction, poetry, and music. He lives in Berkeley, CA. Caleb Zakarin is editor of the New Books Network. Learn more about your ad choices. Visit megaphone.fm/adchoices

We all hope to grow old with dignity and some joyfulness. The intimate narratives of 40 extraordinary elders shared in I'll Fly Away: Stories About Amazing Disabled Elders explore both the challenges of aging and the joys and vibrancy that often persist in the twilight years. Poignant observations of the patients and families by a team of health professionals intersecting daily at the Center for Elders' Independence in Oakland, California, reveal the complexities of aging, identity, amid the assertive persistence of the human spirit. From a couple's summer drive across the Arizona desert to a family's struggle with mental illness to patients' romantic escapades, each tale offers a unique glimpse into the resilience of individuals facing profound transitions and prompts questions about our collective responsibility to our elders. Though this book is valuable for medical and public health professionals, it especially offers families kinship, support, and inspiration. For patients and readers in general, I'll Fly Away champions the idea that every one of us is a unique person with needs, wants, and a voice that is discoverable and deserves to be heard. It embodies the notion that every life is a story, and every voice matters. Marc Sapir, a retired primary care, geriatric and public health physician, is an essayist and political activist. He was first Medical Director of the Center for Elders' Independence for disabled elders for 9 years. He is author of five plays, and also writes fiction, poetry, and music. He lives in Berkeley, CA. Caleb Zakarin is editor of the New Books Network. Learn more about your ad choices. Visit megaphone.fm/adchoices

We all hope to grow old with dignity and some joyfulness. The intimate narratives of 40 extraordinary elders shared in I'll Fly Away: Stories About Amazing Disabled Elders explore both the challenges of aging and the joys and vibrancy that often persist in the twilight years. Poignant observations of the patients and families by a team of health professionals intersecting daily at the Center for Elders' Independence in Oakland, California, reveal the complexities of aging, identity, amid the assertive persistence of the human spirit. From a couple's summer drive across the Arizona desert to a family's struggle with mental illness to patients' romantic escapades, each tale offers a unique glimpse into the resilience of individuals facing profound transitions and prompts questions about our collective responsibility to our elders. Though this book is valuable for medical and public health professionals, it especially offers families kinship, support, and inspiration. For patients and readers in general, I'll Fly Away champions the idea that every one of us is a unique person with needs, wants, and a voice that is discoverable and deserves to be heard. It embodies the notion that every life is a story, and every voice matters. Marc Sapir, a retired primary care, geriatric and public health physician, is an essayist and political activist. He was first Medical Director of the Center for Elders' Independence for disabled elders for 9 years. He is author of five plays, and also writes fiction, poetry, and music. He lives in Berkeley, CA. Caleb Zakarin is editor of the New Books Network. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of Mission Matters, host Adam Torres interviews Dr. Emmanuel Emenike, Founder and Medical Director of Peak Existence, about his data-driven approach to longevity and regenerative medicine. From hyperbaric oxygen to plasma exchange, Emenike discusses the therapies he personally tests before sharing with patients—emphasizing healing, trust, and medical responsibility. Recorded live at the Newport Beach Investor Conference. Big thanks to our sponsor ⁠Brad Turner⁠ and ⁠⁠www.longevityshopping.com Follow Adam on Instagram at ⁠https://www.instagram.com/askadamtorres/⁠ for up to date information on book releases and tour schedule. Apply to be a guest on our podcast: ⁠https://missionmatters.lpages.co/podcastguest/⁠ Visit our website: ⁠https://missionmatters.com/⁠ More FREE content from Mission Matters here: ⁠https://linktr.ee/missionmattersmedia Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this episode of "Coaching Healthcare Leaders," Dr. Lisa interviews Dr. Tanya Harris, a physician specializing in physical medicine and rehabilitation. Dr. Harris shares her inspiring career journey, leadership philosophy, and experiences developing innovative rehabilitation protocols. The discussion highlights the importance of collaboration, active listening, and creating supportive work environments. Dr. Harris addresses challenges in rehabilitation services, including insurance barriers and public misconceptions, and advocates for better systems and education. The episode concludes with practical advice for healthcare leaders on fostering team engagement, finding purpose, and promoting joy in the workplace to enhance patient care. Introduction and Guest Bio (00:00:02) Dr. Lisa introduces the podcast and Dr. Tanya Harris, summarizing her background and achievements in physical medicine and rehabilitation. Early Influences and Career Path (00:03:14) Dr. Harris discusses her early interest in medicine, family influences, and how mentorship led her to physical medicine and rehabilitation. Understanding Physical Medicine and Rehabilitation (00:07:18) Discussion about the field's origins, its under-recognition, and the importance of educating others about rehabilitation services. A Day in the Life of a Medical Director (00:08:20) Dr. Harris describes her daily routine, balancing patient care and staff engagement, and her focus on team collaboration. Leadership Style and Team Empowerment (00:11:19) Dr. Harris explains her “roundtable” leadership style, encouraging all team members to have a voice and fostering inclusivity. Improving Team Collaboration: Practical Example (00:15:55) A real-life example of nurses and therapists collaborating to solve patient care issues, resulting in improved outcomes. Challenges in Rehabilitation Medicine (00:18:41) Dr. Harris outlines major challenges: lack of awareness about rehab services and insurance barriers, and shares strategies to address them. Healthcare Systems: US vs. New Zealand (00:22:36) Comparison of healthcare systems, highlighting New Zealand's dual public-private model and its benefits for patient care and provider costs. Leadership Pearls and Personal Priorities (00:24:20) Dr. Harris shares advice for leaders: set priorities, act with intention, and cultivate personal joy to enhance leadership and care. Closing and Contact Information (00:27:43) Dr. Harris provides her contact details and resources, and Dr. Lisa wraps up the episode.

This episode features Dr. Frederick L. Greene, Emeritus Chair of Surgery at Carolinas Medical Center and Medical Director of Cancer Data Services at Atrium Health-Levine Cancer Institute. Dr. Greene shares insights on improving cancer registries, the evolution of surgical oncology, and the future impact of robotics and AI on healthcare.

May Lin Tao, MD, Medical Director of the Henry Mayo Newhall Hospital and Keck Medicine of USC Cancer program, discusses cancer misinformation, including unproven therapies and other too-good-to-good-be true claims that can often harm patients.

Today's guest is Dr. Christopher Camp, a board-certified orthopaedic surgeon with a deep focus on sports medicine and shoulder and elbow surgery. Since 2019, Dr. Camp has served as the Medical Director, Team Physician, and Director of High Performance for the Minnesota Twins, where he works closely with players, athletic trainers, and front office staff to keep athletes healthy and performing at their best.Beyond the field, Dr. Camp is a leading researcher in the biomechanics of throwing, injury prevention, and surgical innovation. His work is shaping how we understand and treat injuries in overhead athletes—not just in baseball, but across all sports. He also leads the Human Optimization Project at the Mayo Clinic, an initiative focused on maximizing health, performance, and recovery. Listen along as we dive into his unique perspective on athlete care, research, and the evolving relationship between medicine and high performance in professional baseball.For more information about PBATS and athletic training, visit pbats.com.

In this episode, hosts Brad and Michael, along with series regular Jay Reyero, dive into the story of an orthopedic surgeon who agreed to serve as the medical director for a friend's medical spa. What began as a temporary, low-effort role turned into a long-term liability when a demand letter from a patient's attorney uncovered hidden risks. Tune in to learn how to structure a compliant medical director arrangement and the key steps you can take to limit your liability.    Watch full episodes of our podcast on our YouTube channel: https://www.youtube.com/@byrdadatto  Stay connected for the latest business and health care legal updates:WebsiteFacebookInstagramLinkedIn  

We know the increasing use of vapes among teens is an issue we should be concerned about. But when vapes first appeared on the scene, they were largely portrayed as being much safer than cigarettes and experts fear that may have led people to underestimate the risks they pose. Jennifer speaks with Dr Rania Ayat Hawayek, Specialist Paediatrician and the Medical Director at Circle Care Clinic to know the realities of those risks. Meanwhile, a new survey by recruitment firm Robert Walters has revealed a rise in employee turnover here in the UAE - with delays in salary hikes for professionals and white-collar employees cited as taking a toll on workforce stability. While over in the UK, a new government proposal to reduce pay inequality promises, or threatens, to force the publication of information about worker's salaries that would previously have been known only to managers. Does it help make work feel fairer for employees? Or can it also lead to internal conflict and limit flexibility for recruiters and managers? Toby Simpson, Managing Director, Global Head of Executive Search and Lucy D’Abo, Founder of Together workplace culture consultancy discuss. And the region's first Female Majlis on health equity will be aiming to shine a spotlight on a frightening truth: women are diagnosed with disease later, suffer for longer, but often remain unheard in the healthcare system. Jennifer is joined by the event's host, Christina Ioannidis.See omnystudio.com/listener for privacy information.

JCO PO author Dr. Philip Philip at Henry Ford Cancer Institute and Wayne State University shares insights into his JCO PO article, “Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group.” Host Dr. Rafeh Naqash and Dr. Philip discuss how prospective trials are required to clarify the role of ctDNA as a valid surrogate end point for progression-free or overall survival in GI cancers. Transcript Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, Podcast Editor for JCO Precision Oncology and Assistant Professor at the OU Health Stephenson Cancer Center at the University of Oklahoma. Today, we are excited to be joined by Dr. Philip Philip, Chair of Hematology and Oncology, as well as leader of GI and Neuroendocrine Oncology. He's also the Professor of Oncology and Pharmacology, as well as Co-Leader of the Pancreatic Cancer Program and Medical Director of the Cancer Clinical Trial and Translational Research Office at the Henry Ford Cancer Institute at Wayne State University. Dr. Philip is also the Senior Corresponding Author of the JCO Precision Oncology article entitled, "Incorporating Circulating Tumor DNA Testing into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group." At the time of this recording, our guest's disclosures will be linked in the transcript. Dr. Philip, welcome to our podcast, and thank you so much for joining us today. Dr. Philip Philip: Thank you so much, Dr. Naqash, for providing me this opportunity to be discussing this with you. Dr. Rafeh Naqash: This is a very timely and interesting topic. We've done a couple of podcasts on ctDNA before, but none that is an opinion piece or a guidance piece based on what you guys have done. Could you tell us what led to this perspective piece or guidance manuscript being published? There is some background to this. Could you tell us, for the sake of our listeners, what was the initial thought process of why you all wanted to do this? Dr. Philip Philip: The major reason for this was the fact that investigators were considering using ctDNA as a primary endpoint in clinical trials. Obviously, you hear my focus will be on gastrointestinal cancers. So, the idea was, can we use ctDNA instead of using the traditional endpoints such as disease-free survival, progression-free survival, or overall survival? And the question was, do we have enough data to support that in patients with gastrointestinal cancers? Now, the article obviously goes over some review of the data available, but the core of the article was not to do a comprehensive review of ctDNA use and the evidence so far, although we used that in really putting our recommendations. So, we really had to evaluate available data. But the focus was, what are the gaps? What do we need to do? And are we ready to use ctDNA as a primary endpoint in clinical trials? Dr. Rafeh Naqash: Thank you for giving us that background. Obviously, a very broad, complicated topic with a bunch of emerging data that you've highlighted. But most importantly, for the sake of, again, trainees and listeners, could you help us understand the difference between tumor-informed and non-tumor-based ctDNA assessments? Dr. Philip Philip: Sure. So, the tumor-informed is simply meaning that you're taking the genomic makeup or the DNA fingerprint of the cancer in a given patient, and you create a profile, and then use that profile to see whether that DNA is present in the blood. So, it's very simple. It's like barcoding DNA and then going and looking for it in the blood, which means that you have to have the primary tumor. When I say primary tumor, you need to have the tumor to start off with. It doesn't really apply, maybe easily, if you just have a fine-needle aspirate and things like that. So, you really have to have a good amount of the tumor for you to be able to do that. So, that's a tumor-informed, and from the name, you can easily understand how it's done, compared to the other one, which is uninformed, whereby off-the-shelf probes are used to look for tumor DNA. And again, they're based on prior experience and prior identification of the key DNA changes that will be seen in tumors. So, that's the difference between the two in terms of the principle of the test. The uninformed will not require you to send the original tumor that you're trying to test. However, the informed, you do. The turnaround time is, again, a bit different because, as you would expect, it's shorter in the uninformed. And the reason for that, again, is the initial preparation of the profile that is going to be used in the future when you do serial testing. The sensitivity has been a bit of a discussion. Initially, people have thought that tumor-informed assays are more sensitive, more specific, more sensitive, et cetera. But in our review, we come to the conclusion saying that we don't think that's going to be a major difference. And there are obviously improvements happening in both types of assays. The sensitivities have been improving. So, at this point in time, we do feel that you have two types of assays, and we didn't feel strongly about recommending one over the other. Dr. Rafeh Naqash: Thank you for that description. You mentioned something about sensitivity, specificity. Obviously, many of us who have ordered both tumor-informed and tumor-uninformed, we understand the differences with respect to the timing. The tumor-informed one can take more time. The uninformed one, being a sort of a liquid biopsy, may not necessarily have as much of a turnaround time. Could you briefly speak to those limitations or advantages in the context of the two versions? Dr. Philip Philip: I just really want to also highlight that when we say turnaround time, so for the tumor-informed assays, the first assay that we do will be requiring a turnaround time. But once the pattern has been set and the profile has been documented, the subsequent testing doesn't require much in the way of waiting. However, when you're using this for the minimal residual disease, then you have a window of opportunity to work at. That's number one. So, it means that in patients who have resected cancer, you may end up having to wait longer than the tumor-uninformed assay, especially if you don't have easy access to your material for the baseline material to send. And also, what we'd like to do is not do the test immediately after the operation or soon after the operation. Give it some time. There's a window where you can work at, and starting minimally two weeks after the surgery. But in my experience, I'd like to wait at least four weeks just to make sure that we got an accurate reading. Sometimes when you do it very early after surgery, because of the effect of the surgery and the release of the normal DNA is also, it may dilute the tumor DNA, and then you may get a false negative. So, basically, it depends on the clinical situation. And your question is, is one better to be used than the other? I think ultimately, it ends up with the turnaround time not being as much of an issue. It might be in certain situations, depending on when you see the patients after the operation or any definitive treatment you've done and you want to look for minimal residual disease. But in general, I don't think that's going to be a real major issue. Dr. Rafeh Naqash: I remember discussing this with one of the tumor-informed platforms with regards to this barcode you mentioned. They generate a fingerprint of sorts for the tumor on the tissue, then they map it out in the blood and try to assess it longitudinally. And one of the questions and discussions we had was around the fact that most of the time, these barcoded genes are not the driver genes. If you have a KRAS mutant tumor, it's not going to be the KRAS gene that they map out. It's something that is specific. So, is there a possibility that when you are mapping out, let's say, a metastatic tumor where there is truncal and subclonal mutations at different sites, that you capture something that is not necessarily truncal, and that does not necessarily reflect some other metastatic site having a recurrence? So basically, over time, you don't see a specific mutational pattern or the signature on the tumor-informed, and then you see something on the scan which makes you think, "Well, it was not the right test," but actually it could be a different subclone or a clone mutation at a different site. Is there a concept that could help us understand that better? Dr. Philip Philip: I think you raise a very important point. Although, I have to say from my practical experience, that is not a common thing to see. In fact, for some reason, we don't see it that often in any frequency that should, at this point in time, make us concerned about the serial testing. But what you were mentioning is a real challenge which can happen. Now, the question is, how often does the clonal evolution or the divergence happen to the point that it's going to be like a false negative, is what you're saying. At this point in time, we don't really have good information on that, or any good information, practical information. And when we went through the literature and we were looking for the evidence, that wasn't something which was there clearly telling us. Although, this is something that has to be studied further prospectively. And I don't know of a study, but I might be missing it, I don't know of a study which is systematically looking at this. Although it's a very valid hypothesis and theoretical basis for it, but in real life, we still have to see how much does it really interfere with the validity of this kind of testing. Dr. Rafeh Naqash: Which brings us to the more important discussion around your manuscript. And I think that the overarching theme here is the consensus panel that you guys had recommended that ctDNA-based metrics be used as a co-primary endpoint. Could you tell us, for early-phase trials, maybe phase two studies for that matter, could you tell us what were some of the aspects that led to this consensus being formed from your working group? Dr. Philip Philip: Well, there were a number of reasons, in any order of priority, but one of them is we don't have a good sense of dynamics of the ctDNA. And again, remember this article was about gastrointestinal cancers. Maybe we know more about colon cancer, but, or colorectal cancer, but we don't know that well about the upper GI, like gastroesophageal, pancreatic, et cetera. So, we don't know what is the false negative percentages. And in fact, we know that there are certain sites of the disease, metastases, that do not lead to enough shedding of the DNA into the circulation. So, that was something else. I mean, false negativity, not knowing exactly what the dynamics are, especially in different disease types. So, that was another reason, which we felt that it may not be at this time primetime to really have those ctDNA tests as a primary endpoint. We wanted to make sure that, on the other hand, we wanted to make sure that people consider including ctDNA more like a secondary endpoint so that we can gain the information that we're lacking, at least the ones I mentioned to you. So, that was an important point of our discussions and deliberations when we were writing the article. Dr. Rafeh Naqash: And I myself have been on both sides of the aisle where - I treat people with lung cancer, you mentioned appropriately that most of the data that we have for ctDNA is generated from GI cancers, especially colorectal - on the lung cancer side, I myself had a patient with an early-stage cancer, had treatment, surgery, immunotherapy, and then had ctDNA that was tumor-informed, was positive four to five months before the imaging actually showed up. And on the other side, I've also had an individual where early-stage lung cancer, surgery, immunotherapy, and then had PET scans that showed a positive finding, but the ctDNA, tumor-informed ctDNA, was negative multiple times. So, I've seen both aspects of it, and your paper tries to address some of these questions on how to approach a negative, radiologically negative imaging but positive ctDNA potentially, and vice versa. Could you elaborate upon that a little bit? Dr. Philip Philip: Well, obviously, we do see this in practice. Again, I do GI oncology. I have patients who, you do ctDNA. I mean, my advice to anyone, when you order a test, you have to make sure that you know what you're going to do with the test, because that's the most important thing. You get a positive test, you do something. You get a negative test, you do something. But most importantly, our patients who you're following up, they are very anxious for a diagnosis they have that is not- I mean, it's cancer. If you're doing these tests, if we get continuous, repeatedly negative testing, then you really have to also tell the patient that there's a false negativity. And I mentioned to you earlier, there are certain sites of disease, like peritoneal, they may not be producing enough, or there are some tumors, their biology is such that they don't release as much to be detected in the blood. Now, one day we will get maybe a more sensitive test, but I'm talking about the tests we have now. On the other hand, if you get a positive testing, you have to make a distinction for ctDNA in the minimal residual disease situation. If you get a positive test, there is enough evidence that the patient has a worse prognosis. There's evidence for that. No one can dispute that. Again, I'm talking about colorectal cancer where there are a lot of data for that. So, in that situation, there are studies that are looking, if you get a positive test in someone who you're not intending to give any adjuvant treatment, there are studies looking into that, both in terms of intensifying, like chemotherapy, in certain patients. And also, there's work being done, if you have a negative test in someone who has stage III disease, for example, or definitely stage II disease, they may not need to give them chemo. Those things are happening. But in metastatic disease, it's a different situation. Or even in someone who has received surgery, adjuvant chemotherapy, in those patients where they, whether they're now under, in the surveillance mode, those patients, if you have a positive, it may be positive. I had a recent patient like those, eight months before we saw anything on the scans. So, the question is, if you have a positive test, is there any advantage in giving them treatment, systemic treatment? Of course, we're assuming that the PET scan is negative. So, is there really any advantage in giving someone treatment ahead of time, before you see the imaging changes? That kind of data, in my opinion, is not really available or strong. You can always think of it in different ways, explain it in different ways. It's minimal disease, maybe you get a better response. But I don't know if we really can justify at this time. Therefore, in my practice, my own practice, I do not treat just a positive ctDNA. Again, that's different than after surgery when you're thinking of whether to give adjuvant treatment, no adjuvant treatment. But someone who's finished treatments and then you're just serially monitoring the disease, those patients, I do not treat them with chemotherapy. And that was something which, based on the literature we reviewed, there was nothing out there to definitely- I mean, if you see something positive, you will do a scan earlier, you will talk to the patient, examine the patient, whatever. But if there's nothing there, starting a treatment, that's not justified at this point in time. Now, you need to do a study like that. Definitely, you need to do a study. But I can tell you that from my experience, having been involved with study design and all that, it's not an easy trial to do. It's going to be a trial- at a minimum, it will take many patients, it will take longer time to complete, and there are a number of variables there. If someone is willing to put a lot of money into it, it can be done. But I can tell you that that kind of intention to do a study like that has been very much a challenge at this time. Dr. Rafeh Naqash: Of course, as you mentioned, the follow-up time that you need for a study like that is going to be very long to get to meaningful outcomes. Dr. Philip Philip: You need to be very patient to do such a study. But the problem with a very long study is that things change, standard of care changes with time, and the assays will change. So, that's why we don't have that kind of data. I'm not sure if there are people in the community or in the academic centers who do treat based on only positive ctDNA. The other thing is that you really have to always consider the psychological impact of these tests on patients and caregivers. Sometimes it can be really very stressful, burdensome to people to sit there just waiting for the disease to show up on a scan. And therefore, in my opinion, I'm not saying definitely don't use it in that situation, I'm just saying that you have to personalize it also, to see the patient who you would like to do it and then other patients who may not do it, or you think that it's not good for them to do it. And the patient also has to understand the outcome of the test and how you're going to be interpreting it. Dr. Rafeh Naqash: That's a lot of great insights, Dr. Philip, and I know you've been involved in trial designs. I'm sure NCT and cooperative groups are actively thinking and incorporating ctDNA-based metrics as one of the endpoints in their trial. I know of a GU study that's, I think it's an Alliance study, trying to de-escalate treatment based on ctDNA. I have one of my colleagues who's also a GU investigator at OU, he's doing a ctDNA-based, tumor-informed-based de-escalation. So, obviously, more and more data, hopefully, that'll be generated in the next couple of years. Dr. Philip Philip: But remember, these studies are not using it as an endpoint. They're using it as a means of optimizing treatment, which is a bit different. So, as an endpoint, can you do a phase III trial of, let's say, a thousand patients, and your primary endpoint is not survival, but you're saying, "Can I reduce the ctDNA, clear it earlier, or whatever?" That's the sort of thing this article was about. We can't do that at this time. Dr. Rafeh Naqash: I totally understand. Thank you for explaining the difference, and hopefully more to come in this space in the next couple of years. I briefly wanted to touch upon your personal career and journey based on all that you've done and accomplished. Could you tell us about how you started, what your journey has been like, and how that connects with what you're doing right now, including mentoring other trainees and junior faculty? Dr. Philip Philip: Well, when I was in high school, I wanted to be an engineer, but I grew up in Baghdad, and all my friends wanted to do medicine, so I went with the tide, so I did medicine. I don't regret that. I would do it again if I had the opportunity. The reason why I did oncology was, I left the country and did a PhD in clinical pharmacology at the University of London. And that really got me, it was a topic which included, which was on cancer. So, I really got interested in a disease that is really a lot of science, and things are new, or were new at the time. And if I want to look back what I was doing, the beginning of my training in the 80s, second half of the 80s, and now, it's unbelievable how things have changed. But one of the things which I really have to say is that almost all my life I've been in what we call academic institutions. But I firmly believe that for people, whether academic or not, you have to be a very good, astute clinician, because many of the things we do, really, we're trying to put the patients in the center. It's not only doing fancy science, it's to do things that help the patients. And you can bring in bits and pieces of fancy science or less fancy science, but that's something which is really extremely important for us to think about, being a very good clinician, very good doctor, because medicine is a science, whether you're practicing as a solo practitioner or you're part of a large academic center. It's the way you think, the way you interrogate things that you're not sure of, the way you collaborate, the way you learn every day. I mean, at my age, I still don't like to miss any tumor board, because in each tumor board, there's something you learn, even if you think that you know everything. So, that's really the whole thing of it, is that be a very good clinician, be open-minded. Always, you have to think of things that, they look interesting, they look somehow unexplained. Always try to help find the solutions and do that. One of the major things that I feel that people should do is being also very focused on things. I mean, you have to also know what you want to do in the next 5, 10, 15 years. Because although everyone is in it in the same way when we start, but there are different things that drive people, people who want to do more of the formal research, like being an academic-like institution. But there are also a lot of people who are very successful outside of a- what we call an academic setting. In the United States, most people are not working in an academic kind of setting. Although, for me, the distinction between academic and community is getting less and less, because if you think that you do phase I trials in academia only, that's not true, because there are, in fact, in the state of Michigan, the most active phase I doctor is not even in academia, he's in private practice. So, you can do all these things. It's a matter of what you like to do, and you really have to make sure you know what you want to do. Because sometimes people are, especially early on, they get a bit confused, “What I want to do.” There's an issue of doing general oncology versus subspecialist. If you're a subspecialist doing only GI, you have to make sure that you really also have some kind of recognition that you're only a GI oncologist, recognition regional, national, international, but some degree of recognition that you feel that people are coming to you for advice as a second opinion or whatever it is. But again, you have to decide what you think you want to be, how you want to be, because there's a lot of options here between community practice, academic practice, industry, and of course, there's always the administrative thing. Some people tend to be more like going into the line of being an administrator. So, there's a lot of options for you. Dr. Rafeh Naqash: Well, thank you again, Dr. Philip, for those pearls of wisdom. I think that was very insightful. I'm sure all the trainees and early-career investigators will find all that advice very helpful. Thank you again for joining us today. Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review, and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcast. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Dr. Philip Philip Disclosures Honoraria: Bayer, Ipsen, incyte, Taiho Pharmaceutical, Astellas Pharma, BioNTech SE, Novocure, TriSalus Life Sciences, SERVIER, Seagen Consulting or Advisory Role: Celgene, Ipsen, Merck, TriSalus Life Sciences, Daiichi Sankyo, SynCoreBio, Taiho Pharmaceutical Speakers' Bureau: Incyte Research Funding: Bayer (Inst), incyte (Inst), Merck (Inst), Taiho Pharmaceutical (Inst), novartis (Inst), Regeneron (Inst), Genentech (Inst), halozyme (Inst), Lilly (Inst), Taiho Pharmaceutical (Inst), merus (Inst), BioNTech SE (Inst) Uncompensated Relationships: Rafael Pharmaceuticals, Caris MPI  

Dr. Holly Dutton, Medical Director at the Tampa and Clearwater locations of VEG ER for Pets–a national enterprise that specializes in providing around-the-clock emergency and critical care services for pets—flips the script on my mention of the countless guests who work with animals in some capacity, grew up wanting to be a veterinarian, but for […] The post Dr. Holly Dutton, Medical Director VEG ER for Pets first appeared on Talking Animals.

Join us for a powerful and informative Masterclass with Dr. Mark Surrey—world-renowned reproductive surgeon and esteemed member of the Hugh & Grace Advisory Board. As Co-Founder and Medical Director of the Southern California Reproductive Center in Beverly Hills, Dr. Surrey brings decades of groundbreaking expertise to this conversation. From fertility to hormone health to whole-body wellness, this episode offers science-backed insights that every woman should hear.Find us at hughandgrace.com  On Instagram @hughandgrace       On Facebook @HughandGrace   Email us at customercare@hughandgrace.com Music: Realize your dreams by Sergio Prosvirini

Could physician advisors become dinosaurs in healthcare, bound for extinction?The role of the physician advisor has developed into an absolute necessity in hospitals of all sizes around the country. As the healthcare landscape rapidly evolves, physician advisors have served as critical players, bridging the gap between confusion and clarity within clinical and administrative functions.Yet, the question remains unanswered: why are only a fraction of physician advisors employed as full-time employees?During the next live edition of Talk Ten Tuesdays, Juliet B. Ugarte Hopkins, MD, Medical Director of Phoenix Medical Management, Inc., will report on the pitfalls of inadvertently diluting the physician advisor's focus and level of expertise.The popular Internet broadcast will feature the additional following instantly recognizable panelists, who will report more news during their segments:• CDI Report: Cheryl Ericson, Director of clinical documentation integrity (CDI) for the vaunted Brundage Group, will have the latest CDI updates;• The Coding Report: Christine Geiger, Assistant Vice President of Acute and Post-Acute Coding Services for First Class Solutions, will report on the latest coding news;• Field Report: Dennis Jones, a veteran Monitor Mondays and Talk Ten Tuesdays contributing editor, will report on the latest developments regarding the revenue cycle. Jones is the senior director of revenue cycle at Jefferson Health;• News Desk: Timothy Powell, ICD10monitor national correspondent, will anchor the Talk Ten Tuesdays News Desk; and• Point of View: Dr. Kennedy will report on his efforts to advocate for a change in the definition of sepsis. Dr. Kennedy will be sitting in for Angela Comfort, who continues as the co-host for the long-running and popular weekly Internet broadcast.

"Oh, the people you'll meet, and the places you'll go..."That classic Dr. Seuss line couldn't have been more true when I found myself at a rare disease conference, taking with Dr. Gabriel Cohn. A quiet presence with a resume that reads like a roadmap through the last 30 years of rare disease breakthroughs, Dr. Cohn is the kind of person who reminds you just how much heart and science it takes to change lives.Dr. Gabe Cohn is the Executive Director and Medical Director of the Rosenau Family Research Foundation. He stepped into the role in October, bringing with him over three decades of experience that spans academic medicine and the biotechnology industry. A licensed, board-certified Clinical Geneticist and Obstetrician-Gynecologist, Dr. Cohn has contributed to the development of multiple therapeutics aimed at treating rare genetic disorders—a career built on both clinical precision and compassionate innovation.Beyond RFRF, he's also the Chief Medical Officer at iECURE, Inc., a biotech company pioneering gene editing therapies for rare diseases. His prior leadership roles at Homology Medicines, AVROBIO, OvaScience, and Shire reflect a steady focus on advancing gene therapy and editing platforms. Since 2017 alone, he's played a pivotal role in getting five different cell and gene therapy programs past the critical regulatory gatekeeping stages of IND and CTA submissions.Dr. Cohn isn't just a scientist—he's a builder, a connector, and a relentless advocate for the potential of genetic medicine to rewrite the future for patients with rare diseases.If you would like to get a hold of the Rosenau Foundation: https://rosenaufoundation.org Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/en

Dr. Jeremy Silver, MD, Medical Director of Emergency Medicine at Northwestern Medicine Kishwaukee Hospital, joins Dean for this week's health update. This week, Dr. Silver shares medical issues men should be aware of. Some pertaining to heart health, prostate health and more. Then Dr. Silver answers listener questions.

Dean Richards, Dave Schwan, and Andy Masur start off this Father’s Day Sunday by sharing stories about their dads. The guys also give a shoutout to Engineer Bob Ferguson for his 35th work anniversary with WGN Radio. For today's Far Flung Forecast, Dave takes us to Spokane, Washington. Dr. Jeremy Silver, MD, Medical Director of […]

In this episode, I'm joined by a good friend and former colleague, Dr. Naga “Satish” Bodapati, MD — a double board-certified psychiatrist specializing in child, adolescent, and adult psychiatry. With over seven years of experience, Dr. Bodapati brings a wealth of clinical and leadership expertise, shaped by his work as Medical Director at Sunshine Behavioral Health Services, his involvement with the Department of State Hospitals' Incompetent to Stand Trial Program, and his advisory role with NAMI Kern County.Together, we dive into a wide-ranging and meaningful conversation—covering everything from ADHD and Bipolar Disorder to cultural identity, stigma, and the complex realities of mental health care. We explore how our personal backgrounds inform our professional paths and discuss the importance of culturally responsive care, advocacy, and access to treatment.Whether you're a mental health professional, student, or someone curious about the many layers of psychiatry and wellness—this episode offers deep insight, honest reflections, and important takeaways.

Dr. Anna-Michelle McSorley, Assistant Professor in the Department of Allied Health Sciences at the University of Connecticut, details the findings of her recent study on quality of life indicators in three U.S. territories and explains the importance of data from the Behavioral Risk Factor Surveillance System; Christina Severin, Director of Public Health Law at ASTHO, discusses her role on the State Health Policy team in this installment of the Get to Know You segment; ASTHO welcomes new member Dr. John Langefeld, Medical Director for the Kentucky Department for Public Health; the Vermont Department of Health Laboratory received the Excellence in Public Health Response award for a significant contribution to the CDC; and registration is open for the second installment in ASTHO's Essentials of Leadership and Management Series, with the first workshop on strategic communications taking place July 9th.   Study: Health-Related Quality of Life in the US Territories of Puerto Rico, Guam, and the Virgin Islands ASTHO State Health Policy ASTHO's Public Health Legal Mapping Center PHIG Partners: PHIG Infrastructure Grant John Langefeld, MD  Vermont Department of Health Public Health Laboratory CDC Laboratory Response Network for Chemical Threats   ASTHO Workshop: Ignite, Accelerate, and Activate: Series 2, Session 1: Navigating Difficult Conversations

Today, on a special episode, Asif and Ali interview addiction expert Dr. Jason Giles. For over two decades, Dr. Giles has helped more than 10,000 patients overcome substance use disorders. Dr. Giles combines clinical expertise with personal experience, having navigated his own journey to recovery 25 years ago. Dr. Giles is the founder and Medical Director of Addiction Doctors, a leading telemedicine practice specializing in comprehensive addiction care.   Dr. Giles discusses his personal story with addiction and how this led him from anesthesiology to addiction medicine. Asif and Ali then ask Dr. Giles about whether certain jobs or personality types are predisposed to addiction, and then ask about some “hot button issues” including forced addiction treatment,decriminalization of illegal drugs, and if you should pay people to stay sober. They also discuss whether people need to “want” to stop using. They then ask Dr. Giles about inpatient versus outpatient treatment and the role of telemedicine and Ali asks about the role of organizations such as AA and NA.  The opinions expressed are those of the hosts, and do not reflect those of any other organizations. This podcast and website represents the opinions of the hosts. The content here should not be taken as medical advice. The content here is for entertainment and informational purposes only, and because each person is so unique, please consult your healthcare professional for any medical questions.    Music courtesy of Wataboi and 8er41 from Pixabay   Contact us at doctorvcomedian@gmail.com   Follow us on Social media: Twitter: @doctorvcomedian Instagram:  doctorvcomedian

This episode, recorded live at the Becker's 3rd Annual Spring Payer Issues Roundtable, features Dr. Aisha Rahim, Medical Director and Co-Lead, AI Governance Council, Johns Hopkins Health Plans (JHHP). Dr. Rahim discusses how JHHP is leveraging artificial intelligence to manage costs, close care gaps, advance health equity, and enhance member engagement across a diverse population.

Women are generally told that if they have a breast cancer diagnosis, they should steer clear of estrogen. In this episode, I have a conversation with Dr. Swati Kulkarni, the lead investigator of a new study in which women with a newly diagnosed breast ductal carcinoma in situ, DCIS, were given a month's worth of hormone therapy before standard treatment to see the impact it would have on developing cancer cells.  What DCIS is and how it is typically diagnosed. If DCIS is considered to be a pre-cancer or a cancer If DCIS is untreated, how often it will progress to invasive cancer  If treated, how often women with DCIS go on to develop invasive cancer?  Why this particular form of hormone therapy, conjugated estrogens and bazodoxifene (Duovee™) was used in the study The details of the study The results of the study  The Promise Study: A presurgical randomized clinical trial of CE/BZA vs placebo in postmenopausal women with ductal carcinoma in situ. Link to Abstract My summary of the study on Substack https://drstreicher.substack.com/p/can-hormone-therapy-shrink-breast Link to Kagan episode on Duovee with Dr. Kagan Episode 124 All Hormones Are Not Created Equal with Dr. James Simon Dr. Streicher is on SUBSTACK      DrStreicher.Substack.com Articles Monthly newsletter All COME AGAIN podcast episodes Monthly News Flash Reports on recent research  Monthly Zoom Ask Me Anything Webinar  Information on Dr. Streicher's COME AGAIN Podcast- Sexuality and Orgasm https://drstreicher.substack.com/p/all-about-come-again Lauren Streicher MD, is a clinical professor of obstetrics and gynecology at Northwestern University's Feinberg School of Medicine, the founding medical director of the Northwestern Medicine Center for Sexual Medicine and Menopause, and a Senior Research Fellow of The Kinsey Institute, Indiana University. She is a certified menopause practitioner of The Menopause Society. She is the Medical Director of Community Education and Outreach for Midi Health.   Dr. Streicher is the medical correspondent for Chicago's top-rated news program, the WGN Morning News, and has been seen on The Today Show, Good Morning America, The Oprah Winfrey Show, CNN, NPR, Dr. Radio, Nightline, Fox and Friends, The Steve Harvey Show, CBS This Morning, ABC News Now, NBCNightlyNews,20/20, and World News Tonight. She is an expert source for many magazines and serves on the medical advisory board of The Kinsey Institute, Self Magazine, and Prevention Magazine. She writes a regular column for The Ethel by AARP and Prevention Magazine.    LINKS Subscribe To Dr. Streicher's Substack Information About the COME AGAIN Podcast Dr. Streicher's CV and additional bio information To Find a Menopause Clinician and Other Resources  Glossary Of Medical Terminology BOOKS by Lauren Streicher, MD  Slip Sliding Away: Turning Back the Clock on Your Vagina-A gynecologist's guide to eliminating post-menopause dryness and pain Hot Flash Hell: A Gynecologist's Guide to Turning Down the Heat Sex Rx- Hormones, Health, and Your Best Sex Ever The Essential Guide to Hysterectomy                                       Dr. Streicher's Inside Information podcast is for education and information and is not intended to replace medical advice from your personal healthcare clinician. Dr. Streicher disclaims liability for any medical outcomes that may occur because of applying methods suggested or discussed in this podcast.                                     

In this episode, Julie, Stephanie, and Suzanne answer the listeners question of how to differentiate between signs, symptoms, and diagnosis of an AFE v. a PEThe experts at Clinical Concepts in Obstetrics pool their decades of experience caring for critically ill pregnant women to discuss the challenges encountered in caring for these vulnerable women. Dr Stephanie Martin is the Medical Director for Clinical Concepts in Obstetrics and a Maternal Fetal Medicine specialist with expertise in critical care obstetrics. Suzanne McMurtry Baird, DNP, RN is the Nursing Director for Clinical Concepts in Obstetrics with many years of experience caring for critically ill pregnant women. Julie Arafeh, RN, MS is the Simulation Director for Clinical Concepts in Obstetrics and a leading expert in simulation.Critical Care Obstetrics Academy: https://www.clinicalconceptsinob.com/Follow us: Instagram: https://www.instagram.com/criticalcareob/Dr Martin's LinkedIn: http://linkedin.com/in/stephanie-martin-65b07112aCCOB LinkedIn: https://www.linkedin.com/company/clinical-concepts-in-obstetrics/Twitter/X: https://twitter.com/OBCriticalCareCCOB Facebook: https://www.facebook.com/clinicalconceptsinobstetricsDr Ma...

From psychedelic breakthroughs to breaking the boundaries of compassion, Duncan Trussell and Raghu Markus offer unfiltered wisdom on the messy magic of waking up.Take the opportunity to support Ram Dass' Love Serve Remember Foundation and step into another dimension with a one-of-a-kind pair of custom Midnight Gospel sneakers. Hand-crafted by The Shoe Surgeon to replicate the iconic shoes worn by Clancy himself in the groundbreaking animated series by Duncan Trussell and Pendleton Ward. All proceeds benefit the Love Serve Remember Foundation and their work to preserve and continue the teachings of Neem Karoli Baba and Ram Dass. CLICK HERE to bid on the shoes and find more exciting one-of-a-kind collector's items at the LSRF Auction HERE.This time on Mindrolling, Duncan and Raghu connect over: The Good Friday psychedelic experiment New MDMA research with octopuses and insights into social neuroscienceBrain scans of Tibetan monks practicing loving-kindness (Metta) meditation‘Making the most' of the neuroplasticity that can occur during a psychedelic experience The most powerful issue we have to deal with: identity Transactional compassion versus offering genuine love and care to all Reversing our own neurosis and breaking through the self-created boundaries of compassionEmbracing spiritual discipline through the daily grind of practiceMoving through what the Buddhists call ‘the original heart of sadness' Maladaptive behaviors that we develop to mask the pain of humanity Alcohol as the west's faulty ‘ayahuasca' and initiation practice Self-compassion and allowing ourselves to be humanToday's episode is sponsored by Psychedelic Science 2025 & Reunion:Join the most important psychedelic gathering of the year......bridging science, spirit & society at Psychedelic Science 2025: THE INTEGRATION, hosted by the Multidisciplinary Association for Psychedelic Studies. Be part of the movement that will shape the next era of mental health, medicine, and consciousness.Featuring speakers like Paul Stamets, United States Representative Tim Ryan, Rick Doblin, founder of Internal Family Systems (IFS) Richard Schwartz, Pilar Guzman, CEO/Medical Director of the APA Marketa M. Wills, Raghu Markus, comedian Reggie Watts, musicians TYCHO & Jim James, and many more!Listeners get 15% off tickets to the 5-day event with our promo code LSRF15 at PsychedelicScience.orgMindrolling is brought to you by Reunion. Reunion is offering $250 off any stay to the Love, Serve, Remember community. Simply use the code “BeHere250” when booking. Disconnect from the world so you can reconnect with yourself at Reunion. Hotel | www.reunionhotelandwellness.com Retreats | www.reunionexperience.orgAbout Duncan Trussell:Duncan Trussell is a stand-up comedian, podcaster, and actor. His popular podcast, The Duncan Trussell Family Hour, has been downloaded over 25 million times and is known for its blend of humor, fringe ideas, eclectic guests, and great interviews. The DTFH is the foundation for Duncan's Netflix animated series, The Midnight Gospel, which he co-created with Pendleton Ward in 2020. To learn more about Duncan's work, visit his website at duncantrussell.com.“What do you do when you're passing strangers in the street and you love them completely? It's not bullshit. You feel about them the way you feel about someone you love, like your mother. What happens when the boundary of compassion breaks through and there is no longer this person deserves compassion, this person doesn't. It's like a dam broke." – Duncan TrussellSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Many chronic health conditions—such as IBS, asthma, and autoimmune disorders—can be traced back to imbalances in the gut. Disruptions to the microbiome caused by antibiotics, poor diet, food sensitivities, and environmental exposures can lead to inflammation, malabsorption, and increased intestinal permeability (leaky gut). Addressing gut health through a structured Functional Medicine approach called the 5R's of gut repair—removing harmful triggers, replacing missing digestive factors, reinoculating with beneficial bacteria, repairing the gut lining, and rebalancing lifestyle factors—can restore balance and improve systemic health.  In this episode, I discuss, along with Dr. Elizabeth Boham and Raja Dhir, the Functional Medicine approach to healing the gut and why the gut is at the center of imbalances in the body, including many health conditions. Dr. Elizabeth Boham is Board Certified in Family Medicine from Albany Medical School, and she is an Institute for Functional Medicine Certified Practitioner and the Medical Director of The UltraWellness Center. Dr. Boham lectures on a variety of topics, including Women's Health and Breast Cancer Prevention, insulin resistance, heart health, weight control and allergies. She is on the faculty for the Institute for Functional Medicine. Raja Dhir is the co-founder and co-CEO of Seed Health, a microbiome science company developing innovative probiotics and living medicines to advance human and planetary health. He specializes in translating cutting-edge microbial research into impactful products and leads Seed Health's academic collaborations with institutions such as MIT, Harvard, Stanford, Caltech, and the NIH. Raja co-chairs Seed's Scientific Board alongside Dr. Jacques Ravel, guiding research across microbiology, immunology, genetics, and ecology. He also directs LUCA Biologics, a company focused on the vaginal microbiome and women's health, and oversees SeedLabs, which drives environmental initiatives. Through this work, Raja plays a key role in accelerating microbiome-based solutions from discovery to market. This episode is brought to you by BIOptimizers. Head to bioptimizers.com/hyman and use code HYMAN10 to save 10%. Full-length episodes can be found here: What Is Leaky Gut And How Can You Treat It?How to Select a Probiotic and the Future of the MicrobiomeHow To Do The 10-Day Detox

In this interview from 1977, Ram Dass shares his views on psychedelics and how they can provide a free slate to experience the innocence of consciousness once again. Join the most important psychedelic gathering of the year......bridging science, spirit & society at Psychedelic Science 2025: THE INTEGRATION, hosted by the Multidisciplinary Association for Psychedelic Studies. Be part of the movement that will shape the next era of mental health, medicine, and consciousness.Featuring speakers like Paul Stamets, United States Representative Tim Ryan, UCSF Neuroscience & Psychopharmacology Researcher Robin Carhartt-Harris, Rick Doblin, founder of Internal Family Systems (IFS) Richard Schwartz, Pilar Guzman, CEO/Medical Director of the American Psychiatric Association Marketa M. Wills - M.D., M.B.A., FAPA, Raghu Markus, comedian Reggie Watts, musicians TYCHO & Jim James, and many more!Listeners get 15% off tickets to the 5-day event with our promo code LSRF15 at PsychedelicScience.orgThis episode of Here and Now is from an interview with Ram Dass conducted by New Dimensions Radio in 1977, shortly after Ram Dass participated in a conference called “LSD – A Generation Later.” The interview begins with Ram Dass discussing the happenings at the conference and his interactions with other psychedelic luminaries, including Timothy Leary, Ralph Metzner, and Albert Hofmann. Ram Dass explores the culture surrounding LSD in 1977, and how he has no desire to legislate how other people live their lives. He shares his guru's instructions for using the “yogi medicine” and talks about whether or not it's important to have a guide for psychedelic experiences.Finally, Ram Dass cautions that “getting high and seeing” is only one part of the process of change, and there are inner processes necessary to bring about change in life. He discusses the cultural evolution brought about by psychedelics and the shifts in consciousness he sees taking place. The Ram Dass community gathers regularly to engage in meaningful discussions about the podcast. We invite you to join us and share your curiosities, insights, and wisdom. Sign up for the General Fellowship to receive event invitations directly in your inbox.Sponsors of this Episode:This show is sponsored by Magic Mind, a matcha-based energy shot infused with nootropics and adaptogens designed to crush procrastination, brain fog, & fatigue. Check out their new Maxx & Free energy shots and get 60% off your subscription with our code RAMDASS60 at magicmind.com/ramdassmfRam Dass Here & Now is also brought to you by BetterHelp. Give online therapy a try at betterhelp.com/ramdass and get on your way to being your best self.Reunion is offering $250 off any stay to the Love, Serve, Remember community. Simply use the code BeHere250 when booking. Disconnect from the world so you can reconnect with yourself at Reunion. Hotel | www.reunionhotelandwellness.com Retreats | www.reunionexperience.org“If you have a guide, you're calm, and you really want to explore your inner being, I still see LSD as an incredible vehicle for overriding your habitual response patterns, your habits of thought, and giving you a free slate to experience your innocence of consciousness once again.” – Ram DassSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.